Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$1.12 -4.7%	$1.24	$0.64 ▼ $2.92	$45.77M	-0.73	494,260 shs	7,765 shs
DTIL Precision BioSciences	$4.90 -2.4%	$4.66	$3.61 ▼ $11.09	$57.76M	1.52	317,550 shs	41,892 shs
LPTX Leap Therapeutics	$0.29 -2.3%	$0.31	$0.22 ▼ $4.79	$11.95M	-0.27	1.79 million shs	294,954 shs
LTRN Lantern Pharma	$4.08 +0.5%	$4.02	$2.55 ▼ $6.12	$44.06M	1.6	138,544 shs	71,423 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	-0.85%	-1.27%	-23.53%	+10.38%	-8.24%
DTIL Precision BioSciences	+0.20%	+5.91%	+2.66%	+3.29%	-48.35%
LPTX Leap Therapeutics	+1.79%	+7.35%	-11.62%	-20.43%	-89.71%
LTRN Lantern Pharma	+0.25%	-3.10%	+4.91%	+34.88%	-2.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BRNS Barinthus Biotherapeutics	3.1652 of 5 stars	3.5	3.0	0.0	3.8	0.8	1.3
DTIL Precision BioSciences	4.0036 of 5 stars	3.5	1.0	4.6	2.7	1.7	0.6
LPTX Leap Therapeutics	2.5804 of 5 stars	3.0	5.0	0.0	3.3	0.0	0.6
LTRN Lantern Pharma	2.5201 of 5 stars	3.5	3.0	0.0	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	3.00	Buy	$3.00	166.90% Upside
DTIL Precision BioSciences	3.00	Buy	$47.00	859.18% Upside
LPTX Leap Therapeutics	2.00	Hold	$3.38	1,070.25% Upside
LTRN Lantern Pharma	3.00	Buy	$25.00	512.75% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	$14.97M	3.06	N/A	N/A	$2.52 per share	0.45
DTIL Precision BioSciences	$1.26M	45.80	N/A	N/A	$2.89 per share	1.70
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	$0.14 per share	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$1.16 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$61.07M	-$1.73	N/A	N/A	N/A	N/A	-54.70%	-44.75%	11/5/2025 (Estimated)
DTIL Precision BioSciences	$7.17M	-$8.81	N/A	N/A	N/A	-6,205.79%	-176.47%	-69.05%	11/3/2025 (Estimated)
LPTX Leap Therapeutics	-$67.56M	-$1.58	N/A	N/A	N/A	N/A	-237.65%	-155.38%	11/12/2025 (Estimated)
LTRN Lantern Pharma	-$20.78M	-$1.78	N/A	N/A	N/A	N/A	-99.89%	-81.58%	11/6/2025 (Estimated)

Latest LPTX, DTIL, LTRN, and BRNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	LPTX Leap Therapeutics	-$0.29	-$0.40	-$0.11	-$0.40	N/A	N/A
8/13/2025	Q2 2025	LTRN Lantern Pharma	-$0.53	-$0.40	+$0.13	-$0.40	N/A	N/A
8/7/2025	Q2 2025	BRNS Barinthus Biotherapeutics	-$0.29	-$0.52	-$0.23	-$0.52	N/A	N/A
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	-$2.13	-$2.04	-$2.13	$6.27 million	$0.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	7.89	7.89
DTIL Precision BioSciences	0.66	5.18	5.18
LPTX Leap Therapeutics	N/A	1.34	1.34
LTRN Lantern Pharma	N/A	3.52	3.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
DTIL Precision BioSciences	37.99%
LPTX Leap Therapeutics	30.46%
LTRN Lantern Pharma	28.62%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	10.70%
DTIL Precision BioSciences	4.50%
LPTX Leap Therapeutics	7.50%
LTRN Lantern Pharma	8.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.72 million	36.36 million	N/A
DTIL Precision BioSciences	200	11.79 million	11.26 million	No Data
LPTX Leap Therapeutics	40	41.44 million	38.33 million	Optionable
LTRN Lantern Pharma	20	10.80 million	9.88 million	Optionable

LPTX, DTIL, LTRN, and BRNS Headlines

Recent News About These Companies

Lantern Pharma Reports Q2 2025 Earnings and Strategic Progress

August 22, 2025 | msn.com

RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26

August 19, 2025 | miamiherald.comM

RedChip Companies, Inc.: RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26

August 19, 2025 | finanznachrichten.de

Lantern Pharma Narrows Loss in Q2

August 14, 2025 | aol.comA

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

August 13, 2025 | businesswire.com

Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy

August 7, 2025 | theglobeandmail.com

Lantern Pharma (LTRN) Expected to Announce Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Short Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Grows By 109.5%

August 6, 2025 | marketbeat.com

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

August 4, 2025 | businesswire.com

Lantern Pharma (LTRN) Gets a Buy from Lake Street

August 4, 2025 | theglobeandmail.com

Lantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment for Phase 2 HARMONIC Trial in Japan

July 31, 2025 | theglobeandmail.com

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

July 31, 2025 | businesswire.com

Lantern Pharma Appoints Dr. Schalop to Board

July 30, 2025 | msn.com

Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology

July 28, 2025 | theglobeandmail.com

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

July 28, 2025 | businesswire.com

Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

July 26, 2025 | miamiherald.comM

Lantern reports complete response in pretreated Lymphoma patient with LP-284

July 24, 2025 | msn.com

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

July 23, 2025 | businesswire.com

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

July 21, 2025 | businesswire.com

IBN Initiates Coverage of Lantern Pharma Inc.

July 16, 2025 | finance.yahoo.com

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

July 15, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPTX, DTIL, LTRN, and BRNS Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$1.12 -0.06 (-4.72%)

Closing price 03:58 PM Eastern

Extended Trading

$1.12 0.00 (-0.36%)

As of 06:18 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Precision BioSciences NASDAQ:DTIL

$4.90 -0.12 (-2.39%)

Closing price 04:00 PM Eastern

Extended Trading

$5.00 +0.10 (+2.02%)

As of 06:05 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Leap Therapeutics NASDAQ:LPTX

$0.29 -0.01 (-2.30%)

Closing price 04:00 PM Eastern

Extended Trading

$0.29 +0.00 (+0.21%)

As of 05:40 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Lantern Pharma NASDAQ:LTRN

$4.08 +0.02 (+0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$4.09 +0.01 (+0.25%)

As of 04:10 PM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time